CD86 and neoplasm: The union between CTLA-4 and B7-1 (CD80) or B7-2 (CD86), expressed in the antigen-presenting cells, and the interaction between PD-1 and its ligands, PD-L1 or PD-L2 (Programmed Death Ligand-1,-2), commonly expressed by tumor and other cells in the tumor microenvironment (TME), inhibits T cell response.